C.H. Boehringer Sohn AG & Co. is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer in

Ingelheim am Rhein Ingelheim (), officially Ingelheim am Rhein ( en, Ingelheim upon Rhine), is a town in the Mainz-Bingen district in the Rhineland-Palatinate state of Germany. The town sprawls along the Rhine's west bank. It has been Mainz-Bingen's district seat ...

, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. Unlike most large pharmaceutical companies which are listed, the company is private and fully owned by the Boehringer, Liebrecht and von Baumbach families. The company's key areas of interest are:

respiratory diseases Respiratory diseases, or lung diseases, are pathological conditions affecting the organs and tissues that make gas exchange difficult in air-breathing animals. They include conditions of the respiratory tract including the trachea, bronchi, bron ...

, metabolism,

immunology Immunology is a branch of medicineImmunology for Medical Students, Roderick Nairn, Matthew Helbert, Mosby, 2007 and biology that covers the medical study of immune systems in humans, animals, plants and sapient species. In such we can see ther ...

, oncology and diseases of the

central nervous system The central nervous system (CNS) is the part of the nervous system consisting primarily of the brain and spinal cord. The CNS is so named because the brain integrates the received information and coordinates and influences the activity of all par ...

. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations (

EFPIA The European Federation of Pharmaceutical Industries and Associations (EFPIA) is a Brussels-based trade association and lobbying organisation, founded in 1978 and representing the research-based pharmaceutical industry operating in Europe. Throug ...

). The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of

Charlemagne Charlemagne ( , ) or Charles the Great ( la, Carolus Magnus; german: Karl der Große; 2 April 747 – 28 January 814), a member of the Carolingian dynasty, was King of the Franks from 768, King of the Lombards from 774, and the first Em ...

History

Poster for Boeson baking powder, the first patented Boehringer Ingelheim product

1885–1999

*1885: Albert Boehringer buys a small tartar factory in Ingelheim am Rhein; work begins on 1 August. *1886: The factory commences production of

tartaric acid Tartaric acid is a white, crystalline organic acid that occurs naturally in many fruits, most notably in grapes, but also in bananas, tamarinds, and citrus. Its salt, potassium bitartrate, commonly known as cream of tartar, develops naturally ...

for use in the food industry (e.g. in

baking powder Baking powder is a dry chemical leavening agent, a mixture of a carbonate or bicarbonate and a weak acid. The base and acid are prevented from reacting prematurely by the inclusion of a buffer such as cornstarch. Baking powder is used to increas ...

and carbonated beverages). *1893: Albert Boehringer renames the company C. H. Boehringer Sohn (CHBS) after his father, Christoph Heinrich Boehringer. *1893: While experimenting with the production of citric acid, lactic acid is formed. Albert Boehringer develops this process, with the intention of producing lactic acid on a larger scale. *1895: Lactic acid is produced on an industrial scale, and is successful commercially. *1917: Professor

Heinrich Otto Wieland Heinrich Otto Wieland (; 4 June 1877 – 5 August 1957) was a German chemist. He won the 1927 Nobel Prize in Chemistry for his research into the bile acids. Career In 1901 Wieland received his doctorate at the University of Munich while studyin ...

, chemist, future Nobel Prize winner and cousin of Albert Boehringer, sets up the company's research department. *1928: Albert Boehringer purchases Dr. Karl Thomae, a company based in Winnenden near Stuttgart. *1946: Dr. Karl Thomae GmbH is re-opened in Biberach an der Riss with a staff of 70 people. *1954: The company hires former Nazi Fritz Fischer after he is released from jail. Fischer was convicted of war crimes and crimes against humanity at the

Nuremberg Trials The Nuremberg trials were held by the Allies against representatives of the defeated Nazi Germany, for plotting and carrying out invasions of other countries, and other crimes, in World War II. Between 1939 and 1945, Nazi Germany invaded ...

. This has never been corroborated or authenticated. The company supplied the most potent ingredient of

Agent Orange Agent Orange is a chemical herbicide and defoliant, one of the "tactical use" Rainbow Herbicides. It was used by the U.S. military as part of its herbicidal warfare program, Operation Ranch Hand, during the Vietnam War from 1961 to 1971. It ...

. *1955: The Animal Health division is established as the company acquires Pfizer's veterinary programme. *1966: A subsidiary company named ''Boehringer Ingelheim Hellas'' was founded and the company started business in Greece. A new factory was built close to Athens at Koropi *1971: The foreign subsidiary, Boehringer Ingelheim Pharmaceuticals, Inc is founded in Ridgefield, Connecticut (USA). This site is soon expanded, and becomes the company's North American research centre. *1985: The Research Institute of Molecular Pathology (IMP) is established in Vienna through a collaboration with

Genentech Genentech, Inc., is an American biotechnology corporation headquartered in South San Francisco, California. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within ...

; it opens in 1988. *1986: The biotechnological centre in Biberach begins production of

biopharmaceuticals A biopharmaceutical, also known as a biological medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, th ...

from cell cultures. *1998: The merging of Boehringer Ingelheim KG and Dr. Karl Thomae GmbH founds Boehringer Ingelheim Pharma KG.

2000–2016

In 2004 the company acquired STEAG microParts GmbH. In December of the same year the company announced the acquisition of the outstanding shares of Boehringer Ingelheim Shionogi Vetmedica. In June 2008, the company announced its intention to acquire Actimis Pharmaceuticals for $515 million, depending on the performance of Actimis' leading asthma compound AP768. In 2009 through its US subsidiary, Boehringer Ingelheim Vetmedica Inc., acquired a significant portion of the Fort Dodge Animal Health business from Pfizer. In 2010 BI, through its Boehringer Ingelheim Japan Investment GK subsidiary, acquired all outstanding shares of SSP CO., Ltd, with Nippon Boehringer Ingelheim Co., Ltd already holding 60.2% of SSP CO's shares. In August 2012 the company acquired FX125L and the somatotaxin programme from Funxional Therapeutics for an undisclosed sum. In May 2015, the company acquired the investigational drug PXS4728A from Pharmaxis’. In July, the company sold its Roxane business to Hikma Pharmaceuticals Plc for $2.65 billion ($1.18 billion in cash and issue 40 million new Hikma shares). The company also agreed to make cash payments of up to $125 million based on performance milestones. On the same day the company announced it would partner with

Hanmi Pharmaceutical Hanmi Pharmaceutical () is a South Korean pharmaceutical company that is headquartered in Seoul. History 1973 to 2009 Hanmi was founded in 1973 by Lim Sung-ki, who was a pharmacist. It was originally named Lim, Sung-ki Pharmaceutical Co., but ...

to develop and commercialise HM61713, a third generation treatment for EGFR mutation-positive lung cancer. Boehringer also terminated its collaboration with Vitae Pharmaceuticals on a new

BACE Beta-secretase 1, also known as beta-site amyloid precursor protein cleaving enzyme 1, beta-site APP cleaving enzyme 1 (BACE1), membrane-associated aspartic protease 2, memapsin-2, aspartyl protease 2, and ASP2, is an enzyme that in humans is enco ...

program for Alzheimer's. The company sold the rights to

Faldaprevir Faldaprevir was an experimental drug for the treatment of hepatitis C (HCV). It was being developed by Boehringer-Ingelheim and reached Phase III clinical trials in 2011. Boehringer announced in 2014 that it would not pursue approval of the dru ...

, a HCV protease inhibitor to Trek Therapeutics. In July 2016 the company sold the commercialisation rights to BI 655066 ( Risankizumab), to AbbVie for $595 million upfront as well as undisclosed milestone payments and royalties. BI 655066 is a drug in late-stage testing for psoriasis, and in earlier testing for

Crohn's disease Crohn's disease is a type of inflammatory bowel disease (IBD) that may affect any segment of the gastrointestinal tract. Symptoms often include abdominal pain, diarrhea (which may be bloody if inflammation is severe), fever, abdominal distension, ...

, psoriatic arthritis and

asthma Asthma is a long-term inflammatory disease of the airways of the lungs. It is characterized by variable and recurring symptoms, reversible airflow obstruction, and easily triggered bronchospasms. Symptoms include episodes of wheezing, co ...

. In September of the same year the company announced it would acquire ViraTherapeutics for €210 million ($230 million), a developer of oncolytic virus therapies, dependent on the success of Phase I trials.

2016 – Sanofi asset swap

In June 2016, the company announced it had struck an asset-swap deal with

Sanofi Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Sy ...

, Boehringer would sell its consumer health division (valuing it at €6.7 billion) and €4.7 billion in cash, whilst acquiring the

Merial Boehringer Ingelheim Animal Health is a multinational animal health company, formed in January 2017 when Merial was acquired by Boehringer Ingelheim and merged with Boehringer Ingelheim's existing animal health assets. Overview In August 1997, ...

animal health division (valuing it at €11.4 billion / $12.4 billion). The deal could mean that Boehringer is now one of the animal healthcare global leaders. In September of the same year,

Amgen Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen was established in Th ...

announced it would purchase the rights to Boehringer Ingelheims Phase I bispecific T-cell engager compound ( BI 836909, now AMG 420) for use in the treatment of

multiple myeloma Multiple myeloma (MM), also known as plasma cell myeloma and simply myeloma, is a cancer of plasma cells, a type of white blood cell that normally produces antibodies. Often, no symptoms are noticed initially. As it progresses, bone pain, anem ...

. As part of the asset swap, Boehringer and Merial sold a number of assets to Ceva Santé Animale - namely some animal health vaccines and pharmaceuticals from the Merial portfolio for swine, bovine and companion animals, as well as some intellectual property, manufacturing processes and R&D activities. In October 2016 the company sold its US pet vaccines business and a manufacturing plant for $885 million, to Eli Lilly Cos Elanco Animal Health division.

2018–onwards

In April 2018 the company announced that it would launch an immuno-oncology partnership with OSE Immunotherapeutics worth up-to-$1.4 billion, focussing on developing OSE's late-preclinical-stage candidate OSE-172, a checkpoint inhibitor antibody designed to treat solid tumors. In the same month Boehringer announced a partnership with Topas Therapeutics and their virus-based vectors. In mid-September the company exercised its option to acquire viral cancer therapy developer, ViraTherapeutics, for €210 million ($245 million). In March 2019 Boehringer announced it would acquire ICD Therapeutics. In July, subsidiary company Boehringer Ingelheim Pharmaceuticals, Inc. announced it had acquired Amal Therapeutics SA, boostings the business' focus on cancer immunotherapy and vaccine treatments. In May 2020, the business announced it would acquire Northern Biologics Inc. which focuses on therapeutic antibodies targeting tumours. In June, the business announced it would sell off part of its stake in London-listed

Hikma Pharmaceuticals Hikma Pharmaceuticals plc is a British multinational pharmaceutical company with headquarters in London, UK that manufactures non-branded generic and in-licensed pharmaceutical products. It was founded by Samih Darwazah in Amman, Jordan i ...

(28 million out of a 40 million share holding) for around $800 million. In July, the company announced it would acquire Global Stem cell Technology, boosting its animal health business. In December, Boehringer announced it would acquire Labor Dr. Merk & Kollegen, boosting its immuno-oncology therapy range including

Vesicular Stomatitis Virus ''Indiana vesiculovirus'', formerly ''Vesicular stomatitis Indiana virus'' (VSIV or VSV) is a virus in the family '' Rhabdoviridae''; the well-known '' Rabies lyssavirus'' belongs to the same family. VSIV can infect insects, cattle, horses and pi ...

and cancer vaccines platforms and Swiss-based NBE Therapeutics, adding drug candidates including a treatment being used in early trials against

triple-negative breast cancer Triple-negative breast cancer (TNBC) is any breast cancer that lacks or show low levels of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) overexpression and/or gene amplification (i.e. the ...

and lung cancer, for $1.5 billion. In June 2020, Boehringer and

G1 Therapeutics G1 Therapeutics, Inc. is an American biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company specializes in developing and commercializing small molecule therapeutics for the treatment of patients with cance ...

announced a co-promotion agreement for trilaciclib (Cosela), a CDK4/6 inhibitor designed to prevent chemotherapy-induced

myelosuppression Bone marrow suppression also known as myelotoxicity or myelosuppression, is the decrease in production of cells responsible for providing immunity ( leukocytes), carrying oxygen (erythrocytes), and/or those responsible for normal blood clotting ( ...

. The agreement targets

small cell lung cancer Small-cell carcinoma is a type of highly malignant cancer that most commonly arises within the lung, although it can occasionally arise in other body sites, such as the cervix, prostate, and gastrointestinal tract. Compared to non-small cell car ...

, will initially run for three years, and covers the United States and Puerto Rico. In September 2021, the company announced it would acquire Abexxa Biologics, boosting its cancer immunotherapy research.

Business overview

Boehringer Ingelheim works in human pharmaceuticals,

animal health Veterinary medicine is the branch of medicine that deals with the prevention, management, diagnosis, and treatment of disease, disorder, and injury in animals. Along with this, it deals with animal rearing, husbandry, breeding, research on nutr ...

, and

biopharmaceutical A biopharmaceutical, also known as a biological medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, th ...

s. The group consists of 145 affiliated companies with around 50,000 employees in 2017 in all continents. Research and development facilities were in five sites and 20 production plants in 13 countries. The research and development facilities are located in Biberach (Germany), Ridgefield (Connecticut), Vienna,

Kobe Kobe ( , ; officially , ) is the capital city of Hyōgo Prefecture Japan. With a population around 1.5 million, Kobe is Japan's seventh-largest city and the third-largest port city after Tokyo and Yokohama. It is located in Kansai region, whic ...

, and Milan (closed in 2017). Over 8,000 employees work for Boehringer Ingelheim in research and development.

Operational sites

Boehringer Ingelheim is a globally operating company, with 146 subsidiaries around the globe. The company's largest site and corporate headquarters is in Ingelheim am Rhein near Mainz and Frankfurt, Germany. Their main business regions are Europe, North America and Asia. The Research Institute of Molecular Pathology in Vienna (Austria), founded in 1985, has had Boehringer Ingelheim as its main sponsor since 1993.

Closure of Bedford plant

In 2011 Ben Venue Laboratories in

Bedford, Ohio Bedford is a city in Cuyahoga County, Ohio, United States located to the east of Cleveland. The population was 13,074 at the 2010 census. It is an eastern first ring suburb of Cleveland. Geography Bedford is located at . It is a first ring su ...

, a division of Boehringer Ingelheim, voluntarily shut down after a

U.S. Food and Drug Administration The United States Food and Drug Administration (FDA or US FDA) is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food s ...

inspectors' report that found the plant had rusty tools, mold, and a barrel of 'unknown liquid', later found to be

urine Urine is a liquid by-product of metabolism in humans and in many other animals. Urine flows from the kidneys through the ureters to the urinary bladder. Urination results in urine being excreted from the body through the urethra. Cellular m ...

. The company invested to upgrade the drug manufacturing plant, and limited production resumed in October 2012. However, on 3 October 2013, Ben Venue announced that it would be ceasing production by the end of 2013 due to being unable to "return to sustainable production."

Collaborative research and partnership with Google Quantum AI

Boehringer Ingelheim is involved in publicly funded collaborative research projects with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox. The company is expanding its activities in joint research projects within the framework of the

Innovative Medicines Initiative The Innovative Medicines Initiative (IMI) is a European initiative to improve the competitive situation of the European Union in the field of pharmaceutical research. The IMI is a joint initiative ( public-private partnership) of the DG Resear ...

and the European Commission. On January 11th, 2021 Boehringer Ingelheim announced a collaborative agreement with Google Quantum AI (Google), focusing on researching and implementing cutting-edge use cases for quantum computing in pharmaceutical research and development (R&D), specifically including molecular dynamics simulations. Boehringer Ingelheim is the first pharmaceutical company worldwide to join forces with Google in quantum computing in a newly established Quantum Lab of Boehringer Ingelheim. Boehringer Ingelheim is also a founding member of the Quantum Technology and Application Consortium (QUTAC).

Products

Key lines

Prescription Medicines: * Actilyse (

alteplase Alteplase (t-PA), a biosynthetic form of human tissue-type plasminogen activator (t-PA), is a thrombolytic medication, used to treat acute ischemic stroke, acute ST-elevation myocardial infarction (a type of heart attack), pulmonary embolism a ...

) *Aggrenox (

dipyridamole Dipyridamole (trademarked as Persantine and others) is a nucleoside transport inhibitor and a PDE3 inhibitor medication that inhibits blood clot formation when given chronically and causes blood vessel dilation when given at high doses over a ...

acetylsalicylic acid Aspirin, also known as acetylsalicylic acid (ASA), is a nonsteroidal anti-inflammatory drug (NSAID) used to reduce pain, fever, and/or inflammation, and as an antithrombotic. Specific inflammatory conditions which aspirin is used to treat inc ...

) * Alna /

Flomax Tamsulosin, sold under the brand name Flomax among others, is a medication used to treat symptomatic benign prostatic hyperplasia (BPH) and chronic prostatitis and to help with the passage of kidney stones. The evidence for benefit with a k ...

(

tamsulosin Tamsulosin, sold under the brand name Flomax among others, is a medication used to treat symptomatic benign prostatic hyperplasia (BPH) and chronic prostatitis and to help with the passage of kidney stones. The evidence for benefit with a ki ...

) [sold to

] * Aptivus (tipranavir) * Berodual (ipratropium bromide / fenoterol) * Combivent (ipratropium bromide / salbutamol) * Cosela (trilaciclib) * Gilotrif / Giotrif (afatinib) * Jardiance (

empagliflozin Empagliflozin, sold under the brand name Jardiance among others, is an antidiabetic medication used to improve glucose control in people with type2 diabetes, to reduce the risk of cardiovascular death in adults with type2 diabetes and establis ...

) * Jentadueto / TrajentaDuo (

linagliptin Linagliptin, sold under the brand name Tradjenta among others, is a medication used to treat type 2 diabetes (but not type 1) in conjunction with exercise and diet. It is generally less preferred than metformin and sulfonylureas as an initial tr ...

/ metformin) * Metalyse (

tenecteplase Tenecteplase, sold under the trade names TNKase, Metalyse and Elaxim, is an enzyme used as a thrombolytic drug. Tenecteplase is a tissue plasminogen activator (tPA) produced by recombinant DNA technology using an established mammalian cell line ...

) * Micardis (

telmisartan Telmisartan, sold under the brand name Micardis among others, is a medication used to treat high blood pressure, heart failure, and diabetic kidney disease. It is a reasonable initial treatment for high blood pressure. It is taken by mouth. ...

) * Micardis Plus / Micardis HCT ( telmisartan / hydrochlorothiazide) * Mirapex / Sifrol ( pramipexole) * Ofev / Vargatef (

Nintedanib Nintedanib, sold under the brand names Ofev and Vargatef, is an oral medication used for the treatment of idiopathic pulmonary fibrosis and along with other medications for some types of non-small-cell lung cancer. In March 2020, it was approv ...

) * Mobic / Movalis (

meloxicam Meloxicam, sold under the brand name Mobic among others, is a nonsteroidal anti-inflammatory medication (NSAID) used to treat pain and inflammation in rheumatic diseases and osteoarthritis. It is used by mouth or by injection into a vein. It is ...

) * Pradaxa ( dabigatran etexilate) * Spiriva ( tiotropium bromide) * Trajenta / Tradjenta (

) * Twynsta (telmisartan /

amlodipine Amlodipine, sold under the brand name Norvasc among others, is a calcium channel blocker medication used to treat high blood pressure and coronary artery disease. It is taken by mouth. Common side effects include swelling, feeling tired, ...

) * Viramune ( nevirapine) Consumer Health Care (sold to

): * Antistax ( red vine leaf extract) * Bisolvon (

bromhexine Bromhexine is a mucolytic drug used in the treatment of respiratory disorders associated with viscid or excessive mucus. It was developed in the research laboratory of Boehringer Ingelheim in the late 1950s as an active ingredient for pharmaceu ...

) *

Buscopan Hyoscine butylbromide, also known as scopolamine butylbromide and sold under the brandname Buscopan among others, is an anticholinergic medication used to treat crampy abdominal pain, esophageal spasms, renal colic, and bladder spasms. It is al ...

/ Buscapina (

hyoscine butylbromide Hyoscine butylbromide, also known as scopolamine butylbromide and sold under the brandname Buscopan among others, is an anticholinergic medication used to treat crampy abdominal pain, esophageal spasms, renal colic, and bladder spasms. It is a ...

) * Dulcolax (

bisacodyl Bisacodyl ( INN) is an organic compound that is used as a stimulant laxative drug. It works directly on the colon to produce a bowel movement. It is typically prescribed for relief of episodic and chronic constipation and for the management of ...

) * Zantac ( ranitidine)—75 and 150 mg tablets; 300 mg tablets, syrup and solution for injection are manufactured by

GlaxoSmithKline GSK plc, formerly GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company with global headquarters in London, England. Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham. GSK is the tent ...

* Mucoangin / Mucosolvan (

ambroxol Ambroxol is a drug that breaks up phlegm, used in the treatment of respiratory diseases associated with viscid or excessive mucus. Ambroxol is often administered as an active ingredient in cough syrup. It was patented in 1966 and came into med ...

) * Pharmaton (standardized ginseng extract, vitamins, minerals, trace elements) * Silomat / Bisoltussin / Bisolvon Antitussive (

dextromethorphan Dextromethorphan (DXM) is a medication most often used as a cough suppressant in over-the-counter cold and cough medicines. It is sold in syrup, tablet, spray, and lozenge forms. In 2022, the FDA approved a formulation of it combined with b ...

) * Thomapyrin (

, paracetamol, caffeine) * BoxaGrippal (

ibuprofen Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that is used for treating pain, fever, and inflammation. This includes painful menstrual periods, migraines, and rheumatoid arthritis. It may also be used to close a patent ductus arte ...

/ pseudoephedrine) Animal Health: * CircoFLEX (

porcine circovirus Porcine circovirus (PCV) is a group of four single-stranded DNA viruses that are non-enveloped with an unsegmented circular genome. They are members of the genus '' Circovirus'' that can infect pigs. The viral capsid is icosahedral and approxim ...

vaccine type 2, killed ''Baculovirus'' vector) * Duramune (a line of pet vaccines) * Metacam (

) * MycoFLEX ('' Mycoplasma hyopneumoniae'' bacterin) * Vetmedin (

pimobendan Pimobendan (INN, or pimobendane; tradenames Vetmedin, Acardi) is a veterinary medication. It is a calcium sensitizer and a selective inhibitor of phosphodiesterase 3 (PDE3) with positive inotropic and vasodilator effects. Pimobendan is used in t ...

) * Pexion (

imepitoin Imepitoin (), sold under the brand name Pexion, is an anticonvulsant which is used in veterinary medicine in Europe to treat epilepsy in dogs. It was recently approved in the United States. The drug also has anxiolytic effects. It was originally ...

)

Product pipeline

Boehringer Ingelheim's product pipeline targets

lung disease The lungs are the primary organs of the respiratory system in humans and most other animals, including some snails and a small number of fish. In mammals and most other vertebrates, two lungs are located near the backbone on either side of ...

, cancer, and hepatitis C.

Litigation

In October 2012 Boehringer Ingelheim settled a "qui tam" (whistleblower) case with the U.S. government for $95 million alleging "off-label" marketing of the drugs Aggrenox, Atrovent, Combivent, and Micardis for uses that weren't approved by the US Food and Drug Administration and were not covered by federal health care programs. In August 2012, Pradaxa claims filed in the federal court were consolidated in a multi-district litigation in the Southern District of Illinois before Chief Judge David R. Herndon. On 28 May 2014, a $650 million settlement was announced on behalf of approximately 3,900 claimants who were injured by the drug Pradaxa made by Boehringer Ingelheim Pharmaceuticals, Inc. The drug is alleged to cause severe bleeding events and/or hemorrhaging to those who were taking the drug.

Ownership and leadership

As a private company, Boehringer Ingelheim (BI) is not required to disclose detailed financial information publicly; the owners have considered an

IPO An initial public offering (IPO) or stock launch is a public offering in which shares of a company are sold to institutional investors and usually also to retail (individual) investors. An IPO is typically underwritten by one or more investment ...

and ruled it out. In 2006, the Chairman of the Shareholders’ Committee Dr Heribert Johann retired and Christian Boehringer took over the position as

chairperson The chairperson, also chairman, chairwoman or chair, is the presiding officer of an organized group such as a board, committee, or deliberative assembly. The person holding the office, who is typically elected or appointed by members of the grou ...

of the

board of directors A board of directors (commonly referred simply as the board) is an executive committee that jointly supervises the activities of an organization, which can be either a for-profit or a nonprofit organization such as a business, nonprofit organiz ...

. As of 2018 Christian Boehringer remains in this position. In 2015, then-CFO Hubertus von Baumbach took over the position of Chairman of the Board of Managing Directors, a

CEO A chief executive officer (CEO), also known as a central executive officer (CEO), chief administrator officer (CAO) or just chief executive (CE), is one of a number of corporate executives charged with the management of an organization especially ...

position, to replace Andreas Barner who took the position in 2009.

References

External links

* * {{Authority control Biotechnology companies of Germany Multinational companies headquartered in Germany Companies based in Rhineland-Palatinate German brands Pharmaceutical companies of Germany Chemical companies of Germany Pharmaceutical companies established in 1885 German companies established in 1885 Medical and health organisations based in Rhineland-Palatinate